Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tedizolid - Merck & Co

Next Previous
Drug Profile

Tedizolid - Merck & Co

Alternative Names: BAY 1192631; DA-70157; DA-70218; DA-7157; DA-7218; MK-1986; SIVEXTRO; Sivextro; Tedizolid phosphate; Torezolid; Torezolid phosphate; TR-700; TR-701; TR-701 FA; TR-701 free acid

Latest Information Update: 01 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST; Merck & Co
  • Class Anti-infectives; Antibacterials; Fluorinated hydrocarbons; Oxazolidinones; Phosphates; Pyridines; Small molecules; Sodium compounds; Tetrazoles
  • Mechanism of Action Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase III Nosocomial pneumonia; Ventilator associated pneumonia
  • No development reported Bacteraemia; Gram-positive infections

Most Recent Events

  • 08 Aug 2024 Merck completes a phase I trial in healthy volunteers in USA (PO) (NCT06609161)
  • 16 Jul 2024 Merck initiates a phase I trial in healthy volunteers in USA (PO) (NCT06609161)
  • 06 Jul 2023 Merck & Co completes a phase-III trial in Skin and soft tissue infections (In children, In infants) in US, Georgia, Guatemala, Latvia, Lithuania, Russia, Ukraine, Turkey, South Africa, Poland, Mexico, Germany, Bulgaria and Brazil (IV) (NCT03176134)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top